ECSP10010531A - Cristal de compuestos de bencimidazol - Google Patents
Cristal de compuestos de bencimidazolInfo
- Publication number
- ECSP10010531A ECSP10010531A EC2010010531A ECSP10010531A ECSP10010531A EC SP10010531 A ECSP10010531 A EC SP10010531A EC 2010010531 A EC2010010531 A EC 2010010531A EC SP10010531 A ECSP10010531 A EC SP10010531A EC SP10010531 A ECSP10010531 A EC SP10010531A
- Authority
- EC
- Ecuador
- Prior art keywords
- bencimidazol
- composite crystal
- methyl
- crystal
- trifluoroethoxy
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 abstract 1
- 239000003699 antiulcer agent Substances 0.000 abstract 1
- 238000002050 diffraction method Methods 0.000 abstract 1
- 239000000428 dust Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se provee un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridinil]metil]sulfinil]-1H-bencimidazol que muestra un patron de analisis de difraccion de rayos X de polvo con picos caracteristicos en espacios interplanos (d) de 10,06±0,2, 8,70±0,2, 6,57±0,2, 5,59±0,2 y 4,00±0,2 Angstroms. La presente invencion provee un farmaco anti·lcera estable superior en la absorbabilidad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008059342 | 2008-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010531A true ECSP10010531A (es) | 2010-11-30 |
Family
ID=40577894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010531A ECSP10010531A (es) | 2008-03-10 | 2010-10-08 | Cristal de compuestos de bencimidazol |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8222422B2 (es) |
| EP (1) | EP2262790B1 (es) |
| JP (3) | JP2011513202A (es) |
| KR (1) | KR20100123758A (es) |
| CN (1) | CN102026994B (es) |
| AR (1) | AR070972A1 (es) |
| AU (1) | AU2009224247B2 (es) |
| BR (1) | BRPI0909651A2 (es) |
| CA (1) | CA2671369C (es) |
| CL (1) | CL2009000547A1 (es) |
| CO (1) | CO6300956A2 (es) |
| CR (1) | CR11707A (es) |
| DO (1) | DOP2010000274A (es) |
| EA (1) | EA017064B1 (es) |
| EC (1) | ECSP10010531A (es) |
| ES (1) | ES2638463T3 (es) |
| GE (1) | GEP20125649B (es) |
| IL (1) | IL207867A0 (es) |
| LT (1) | LT2262790T (es) |
| MA (1) | MA32215B1 (es) |
| MX (1) | MX2010009641A (es) |
| MY (1) | MY150833A (es) |
| NZ (1) | NZ588379A (es) |
| PE (1) | PE20091680A1 (es) |
| PT (1) | PT2262790T (es) |
| TW (1) | TWI447110B (es) |
| UA (1) | UA103189C2 (es) |
| UY (1) | UY31695A (es) |
| WO (1) | WO2009113696A1 (es) |
| ZA (1) | ZA201006754B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011004387A2 (en) | 2009-06-18 | 2011-01-13 | Matrix Laboratories Ltd | Process for the preparation of dexlansoprazole polymorphic forms |
| CN102108077B (zh) * | 2009-12-23 | 2013-09-25 | 江苏豪森医药集团有限公司 | 制备右兰索拉唑的方法 |
| US20130197232A1 (en) * | 2010-01-29 | 2013-08-01 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline forms of dexlansoprazole |
| CN104447695A (zh) * | 2013-11-22 | 2015-03-25 | 广东东阳光药业有限公司 | 一种苯并咪唑化合物的水合物 |
| WO2016200148A1 (ko) | 2015-06-08 | 2016-12-15 | 씨제이헬스케어 주식회사 | 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도 |
| EP3548497A4 (en) * | 2016-11-29 | 2020-09-02 | Censa Pharmaceuticals Inc. | SEPIAPTERIN POLYMORPHS AND THEIR SALTS |
| CN110312721A (zh) | 2016-11-29 | 2019-10-08 | 显莎制药公司 | 墨蝶呤的多晶型物 |
| CN106866631A (zh) * | 2017-04-06 | 2017-06-20 | 山东裕欣药业有限公司 | 一种右旋兰索拉唑晶型及制备方法 |
| EP3675863A4 (en) | 2017-09-01 | 2021-01-27 | PTC Therapeutics MP, Inc. | PHARMACEUTICAL COMPOSITIONS WITH SEPIAPTERIN AND USES THEREOF |
| EP4349403A3 (en) * | 2018-05-25 | 2024-06-05 | Cardurion Pharmaceuticals, Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one |
| JPWO2020013330A1 (ja) | 2018-07-13 | 2021-06-24 | 協和発酵バイオ株式会社 | ユーコミン酸の非溶媒和物結晶及びその製造方法 |
| CN113376273B (zh) * | 2021-06-02 | 2023-03-17 | 国药集团精方（安徽）药业股份有限公司 | 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| DK171989B1 (da) | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
| DE4035455A1 (de) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
| SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| GB9423968D0 (en) | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
| HRP960232A2 (en) | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| HUP9904073A3 (en) | 1996-11-22 | 2000-04-28 | Procter & Gamble | Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| ATE207065T1 (de) * | 1997-08-08 | 2001-11-15 | Aventis Pharma Gmbh | Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid |
| CA2320963A1 (en) | 1998-01-30 | 1999-08-05 | Sepracor, Inc. | R-lansoprazole compositions and methods |
| AU2481899A (en) | 1998-01-30 | 1999-08-16 | Sepracor, Inc. | S-lansoprazole compositions and methods |
| AU3596199A (en) | 1998-05-06 | 1999-11-23 | Kobenhavns Universitet | Treatment of celiac disease |
| JP3283252B2 (ja) * | 1999-06-17 | 2002-05-20 | 武田薬品工業株式会社 | ベンズイミダゾール化合物の結晶 |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| JP3374314B2 (ja) * | 2000-05-15 | 2003-02-04 | 武田薬品工業株式会社 | 結晶の製造法 |
| JP4327424B2 (ja) * | 2000-05-15 | 2009-09-09 | 武田薬品工業株式会社 | 結晶の製造法 |
| EP1897877B1 (en) | 2000-05-15 | 2014-09-24 | Takeda Pharmaceutical Company Limited | Crystalline forms of (R)-lanzoprazole |
| CA2436825C (en) * | 2000-12-01 | 2011-01-18 | Takeda Chemical Industries, Ltd. | Process for the crystallization of (r)- or (s)-lansoprazole |
| JP4160293B2 (ja) * | 2000-12-01 | 2008-10-01 | 武田薬品工業株式会社 | 結晶の製造法 |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| CA2771725C (en) | 2002-10-16 | 2015-08-18 | Takeda Pharmaceutical Company Limited | Solid preparation comprising a non-toxic base and a proton pump inhibitor |
| US20100286400A1 (en) | 2007-12-31 | 2010-11-11 | Takeda Pharmaceutical Company Limited | Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole |
-
2009
- 2009-03-09 UA UAA201011966A patent/UA103189C2/ru unknown
- 2009-03-09 AR ARP090100831A patent/AR070972A1/es not_active Application Discontinuation
- 2009-03-09 MX MX2010009641A patent/MX2010009641A/es active IP Right Grant
- 2009-03-09 PE PE2009000341A patent/PE20091680A1/es not_active Application Discontinuation
- 2009-03-09 EA EA201071053A patent/EA017064B1/ru not_active IP Right Cessation
- 2009-03-09 NZ NZ588379A patent/NZ588379A/en not_active IP Right Cessation
- 2009-03-09 PT PT97194831T patent/PT2262790T/pt unknown
- 2009-03-09 AU AU2009224247A patent/AU2009224247B2/en not_active Ceased
- 2009-03-09 CN CN200980116767.8A patent/CN102026994B/zh active Active
- 2009-03-09 ES ES09719483.1T patent/ES2638463T3/es active Active
- 2009-03-09 US US12/921,682 patent/US8222422B2/en active Active
- 2009-03-09 MY MYPI20104206 patent/MY150833A/en unknown
- 2009-03-09 GE GEAP200911968A patent/GEP20125649B/en unknown
- 2009-03-09 UY UY0001031695A patent/UY31695A/es not_active Application Discontinuation
- 2009-03-09 CL CL2009000547A patent/CL2009000547A1/es unknown
- 2009-03-09 JP JP2010535143A patent/JP2011513202A/ja active Pending
- 2009-03-09 BR BRPI0909651A patent/BRPI0909651A2/pt not_active IP Right Cessation
- 2009-03-09 TW TW098107510A patent/TWI447110B/zh active
- 2009-03-09 KR KR1020107022471A patent/KR20100123758A/ko not_active Ceased
- 2009-03-09 WO PCT/JP2009/054970 patent/WO2009113696A1/en not_active Ceased
- 2009-03-09 EP EP09719483.1A patent/EP2262790B1/en active Active
- 2009-03-09 CA CA2671369A patent/CA2671369C/en active Active
- 2009-03-09 LT LTEP09719483.1T patent/LT2262790T/lt unknown
-
2010
- 2010-08-30 IL IL207867A patent/IL207867A0/en unknown
- 2010-09-10 DO DO2010000274A patent/DOP2010000274A/es unknown
- 2010-09-21 ZA ZA2010/06754A patent/ZA201006754B/en unknown
- 2010-09-30 CR CR11707A patent/CR11707A/es not_active Application Discontinuation
- 2010-10-07 MA MA33231A patent/MA32215B1/fr unknown
- 2010-10-07 CO CO10124417A patent/CO6300956A2/es not_active Application Discontinuation
- 2010-10-08 EC EC2010010531A patent/ECSP10010531A/es unknown
-
2013
- 2013-09-27 JP JP2013202604A patent/JP2014015477A/ja active Pending
-
2015
- 2015-04-27 JP JP2015090379A patent/JP2015163623A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010531A (es) | Cristal de compuestos de bencimidazol | |
| ATE498618T1 (de) | Neue zyklische harnstoffderivate, deren herstellung und pharmazeutische verwendung damit als kinase-inhibitoren | |
| ATE430145T1 (de) | 3-ä(2-ä 4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü -propionsäure- ethylester -methansulfonat und dessen verwendung als arzneimittel | |
| BRPI0508259A (pt) | derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo | |
| EP2292612A3 (en) | Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole | |
| DE502005007786D1 (de) | Ausgewahlte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
| CA2677201A1 (en) | Solid preparation comprising alogliptin and pioglitazone | |
| AR031069A1 (es) | Cristal de un compuesto benzimidazol, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima | |
| PT1974017E (pt) | Meios e métodos para influenciar a estabilidade de células produtoras de anticorpo | |
| NO20084915L (no) | Nikotinacetylcholinreseptorligander 101 | |
| ATE478066T1 (de) | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel | |
| PL1939204T3 (pl) | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja farmaceutyczna oraz jej zastosowanie medyczne | |
| ITTO20040125A1 (it) | Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica | |
| ATE538125T1 (de) | Neue 2-azaindol-derivate, deren herstellung und pharmazeutische verwendung als kinase-inhibitoren | |
| DE602005003453D1 (de) | Neue effektor-konjugate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
| DE602006001590D1 (de) | 7-(2-(4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isochinolin-besylatsalz, dessen herstellung und dessen therapeutische verwendung | |
| EP2117037A4 (en) | INTERIOR LAYER INSULATION FILM, CONNECTING STRUCTURE AND MANUFACTURING METHOD THEREFOR | |
| CR8955A (es) | Hexadecasacaridos biotinilados, su preparacion y su utilizacion | |
| EP1812367A4 (en) | PROCESS FOR PREPARING 1,2,2,2-TETRAFLUOR-ETHYL-DIFLUOR-METHYL ETHER | |
| EP2167453A4 (en) | PROCESS FOR PREPARING 1,2,2,2-TETRAFLUOROETHYLDIFLUOROMETHYL ETHER (DESFLURAN) | |
| AP2007004147A0 (en) | Process and methods for the preparation of optically active CIS-2-hydroxymethyl-4-(cytosin-1'-YL)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | |
| DE602006008971D1 (de) | N-ä(4,5-diphenylpyrimidin-2-yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung | |
| TN2010000400A1 (en) | Crystal of benzimidazole compound | |
| JP2005519866A5 (es) | ||
| DE602006009939D1 (de) | Heteroarylethenyl-derivate sowie ihre herstellung und verwendung als pharmazeutische mittel |